Results from Paltusotine Carcinoid Syndrome Open Label Phase 2 Study  A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Exhibit 99.2

SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the strategic objectives for paltusotine; the plans and timelines for the clinical development of paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of topline results data from the ongoing Phase 3 clinical study of paltusotine in acromegaly; the expected timing of the submission of a new drug application for paltusotine for the treatment of acromegaly and related open label extension studies; plans and timing for sharing the full results of the Phase 2 study of paltusotine in carcinoid syndrome with the FDA to align on a Phase 3 program and the plans and enrollment in related open label extension studies; the potential benefits of CRN04894 in patients with Congenital Adrenal Hyperplasia or Cushing’s Disease and the expected plans and timing for data and topline data readouts from ongoing clinical studies; the potential benefits of PTH receptor antagonists for patients with hyperparathyroidism, the potential benefits of TSH antagonist for Graves’ Disease or thyroid eye disease; the potential for any of our ongoing clinical studies to show safety or efficacy; the potential of our ongoing discovery efforts to target future indications for hyperparathyroidism, polycystic kidney disease, Graves diseases, thyroid eye disease, or diabetes/obesity, and the expected plans and timing for candidate selection and clinical development of such candidates; our plans to identify and create new drug candidates for additional diseases or the potential for any such new drug candidates to show safety or efficacy; the direction or trajectory of the Company’s potential future growth, the receipt of any revenues from product sales and the ability of such revenues to support continued growth, and our expected plans and timing for commercialization of paltusotine and other product candidates pending regulatory approval. In some cases, you can identify forward-looking statements by terms such as “may,” “believe,” “anticipate,” “could,” “should,” “estimate,” “expect,” “intend,” “plan,” “project,” “will,” “contemplate,” “predict,” “continue,” “forecast,” “aspire,” ”lead to,” “designed to,” “goal,” “potential,” “target” or the negative of or other similar terms.   These statements speak only as of the date of this presentation, involve known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation: topline and initial data that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; the risk that preliminary results of preclinical studies or clinical studies do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available, the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the FDA or other regulatory agencies may require additional clinical studies of paltusotine or suggest changes to our planned Phase 3 clinical studies prior to and in support of the approval of a New Drug Application or applicable foreign regulatory approval; international conflicts may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical studies, nonclinical studies and preclinical studies for paltusotine; regulatory developments or price restrictions in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect; and other risks described under the heading “Risk Factors” in documents we file from time to time with the Securities and Exchange Commission (“SEC”). Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This presentation also contains information gathered from market research, estimates and other statistical data made by independent parties and by us relating to addressable patients, addressable market size and other data about our industry or the potential market opportunity for our product, including academic and community medical oncologist and other HCP opinions collected during market research. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to the opinions gathered in market research or to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. CRINETICS PHARMACEUTICALS |

CRINETICS PHARMACEUTICALS | ✓ ✓ EFFICACY FINDINGS: Rapid and Sustained Reductions in Patient Symptoms SAFETY Once Daily Oral Paltusotine Showed Positive Results in Carcinoid Syndrome Patients  ✓ Efficacy and safety findings support progressing to a pivotal phase 3 trial (pending discussions with the FDA) Paltusotine is an investigational drug in clinical studies for the treatment of acromegaly and carcinoid syndrome. Flushing: 63% reduction in frequency for patients with >1/day (p< 0.0001) Flushing Severity: 61% reduction in severity of episodes (p<0.0001) Excess Bowel Movement: 60% reduction in frequency for patients with >3/day (p=0.02) Bowel Movement Urgency: 64% reduction in urgent episodes (p<0.0001) ✓ ✓ ✓ ✓ ✓ Paltusotine was generally well-tolerated with no treatment-related severe or serious adverse events Paltusotine demonstrated no new safety signals

Paltusotine: Designed to Allow People with Acromegaly and Carcinoid Syndrome to Focus on Living *Pending alignment with FDA on phase 3 study for Carcinoid Syndrome. Paltusotine is an investigational drug in clinical studies for the treatment of acromegaly and carcinoid syndrome. CURRENT STANDARD OF CARE PALTUSOTINE TARGET PRODUCT PROFILE* References  1. Geer EB, Sisco J, Adelman DT, et al. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord. 2020;20(1):117. doi:10.1186/s12902-020-00595-4; 2. Strasburger CJ, Karavitaki N, Störmann S, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol. 2016;174(3):355-62. doi:10.1530/EJE-15-1042; 3. Fleseriu et al. Frontiers in Endocrinology; March 2021, Vol.12; 4. Boyd et al. Pancreas 2013;42: 878—882. VS Inconsistent Symptom Control 77% report injection site reactions Painful, inconsistent and inconvenient dosing Reliable, consistent, and durable control Well- tolerated Once-daily oral tablet No injections CRINETICS PHARMACEUTICALS | Phase 3 design strategy

Carcinoid Syndrome is a Serious Disease and Patients Need Better Treatment Options NETs = Neuroendocrine tumors; SRL = somatostatin receptor ligand. Lung Pancreas NETs Intestine Serotonin + Other Factors Carcinoid Syndrome ~33,000 Patients Diagnosed with Carcinoid Syndrome (U.S.) Facial Flushing in a patient with carcinoid syndrome Courtesy of Stephen E Goldfinger, MD Excess bowel movements (>3/day) are highly disruptive Goal: reduce frequency and urgency (normal is ≤3/day) Severe flushing episodes can be debilitating and potentially dangerous Goal: reduce frequency and severity (normal is < 1/day) Severe and life-threatening complications: carcinoid heart disease (found in up to 50% of patients) & carcinoid crisis Goal: prevent severe complications Injected SRLs impose a high burden of care and frequently lose effectiveness before next injection Goal: eliminate depot and rescue injections and provide consistent control throughout the month CRINETICS PHARMACEUTICALS |

1 Primary Endpoint Safety and tolerability of Paltusotine Phase 2 Study Design: Evaluating Safety, PK and Efficacy of Paltusotine in Carcinoid Syndrome Patients CRINETICS PHARMACEUTICALS | EoT = end of treatment; NET = Neuroendocrine tumor; PK = Pharmacokinetics; PRO = patient reported outcome; SRL = somatostatin receptor ligand; SSTR = somatostatin receptor. Randomized Treatment Phase (RTP) Screening Baseline Long Term Extension 40 or 80 or 120 mg Paltusotine 80 mg Paltusotine 40 mg Paltusotine R RANDOMIZE to 40 mg or 80 mg/d 0d w2 w4 w8 +/-40 mg DOSE ADJUST If needed NO DOSE CHANGE w58 EoT Key Eligibility Criteria:  Treatment naïve or currently untreated and actively symptomatic –OR- controlled on SRL therapy and symptom worsening upon washing out of treatment Positive SSTR expression  Grade 1 or 2 NET Protocol: 8-week, open-label, parallel, randomized 2-dose study followed by a Long Term Extension phase Secondary Endpoint Pharmacokinetics of Paltusotine Exploratory Efficacy Endpoints Bowel movement and flushing frequency and severity markers, octreotide rescue use, biomarkers, PRO measures -7d Washout/Worsening On SRL Participants Naïve/Untreated 2

Subject Disposition and Dosing RTP = Randomized treatment phase (8 weeks); OLE=Open-label extension. 1. One subject who discontinued in the RTP dosed with paltusotine and had diary data through week 8 of the RTP. Total n (%) Entered RTP 36 Naïve/Untreated 9 Switching 27 Discontinued 6 (17) Withdrawal by subject 1 (3) Adverse event 2 (6) Investigator decision 2 (6) Need for administration of a prohibited concomitant medication 1 (3) Increased dose at Week 2 or 4 9 Completed RTP 30 (83) Naïve/Untreated 8  Switching 22 Enrolled in OLE 26 (87) Early Termination1 N=6 Entered RTP N=36 Completed RTP N=30 Enrolled in OLE N=26 CRINETICS PHARMACEUTICALS | Final Dose in RTP: 40 mg N=11 80 mg N=17 120 mg N=2

Baseline Demographics and Disease Characteristics were Consistent Across Patient Groups BMI=Body Mass Index; NET = Neuroendocrine tumor. Naïve/Untreated Symptomatic N=9 Switching from SRL N=27 Overall N=36 Female, n (%) 6 (67) 13 (48) 19 (53) Male, n (%) 3 (33) 14 (52) 17 (47) Age - Mean (SD), years 58.2 (19.5) 61.6 (10.3) 60.8 (13.0) BMI - Mean (SD), kg/m2 30.0 (14.0) 28.4 (5.3) 28.8 (8.1) Geographic Region North America, n (%) 4 (44) 15 (56) 19 (53) Europe, n (%) 1 (11) 1 (4) 2 (6) Latin America , n (%) 4 (44) 11 (41) 15 (42) Duration Since Carcinoid Syndrome Diagnosis – Median, months 8.2 72.1 69.4 NET Tumor Grade 1, n (%) 5 (56) 14 (52) 19 (53) NET Tumor Grade 2, n (%) 4 (44) 13 (48) 17 (47) CRINETICS PHARMACEUTICALS |

Paltusotine Exposure in Patients with Carcinoid Syndrome was Consistent with Expectations from Healthy Volunteers Healthy volunteers: simulated (n=1000) using paltusotine population PK model, sampling at steady-state trough and 2h post-dose. Carcinoid Syndrome patients: 40 mg trough (n=17), 40 mg post-dose (n=15), 80 mg trough (n=21), 80 mg post-dose (n=18), 120 mg trough (n=2), and 120 mg post-dose (n=2). 120 mg data omitted due to small sample size. Mean (SD) Steady-State Paltusotine Concentration (ng/mL) Dose and Sampling CRINETICS PHARMACEUTICALS |

Paltusotine was Generally Well-Tolerated with No Severe or Serious Treatment-Related Adverse Events * The fatal outcome of one SAE (cardiac failure, most likely secondary to carcinoid heart disease) occurred 26 days after treatment discontinuation and was not treatment related. ECG = Electrocardiogram; SAE = Serious Adverse Event. Treatment-Emergent Adverse Events, n (%)  Paltusotine N=36 Any 26 (72.2) Mild/Moderate 22 (61.1) Severe 4 (11.1) Leading to discontinuation 2 (5.6) Serious 4 (11.1) Death 1 (2.8)* Treatment-related 16 (44.4) Mild/Moderate 16 (44.4) Severe 0 Leading to discontinuation 0 Serious 0 Death 0 Preliminary Safety Summary from Ongoing Carcinoid Syndrome Phase 2 Study Paltusotine was generally well-tolerated with no treatment related severe or serious adverse events  Adverse event findings were similar across paltusotine dosing of 40 and 80 mg No new safety signals have been observed during study monitoring of vital signs, ECGs, or safety laboratory values  CRINETICS PHARMACEUTICALS |

Most Frequent Treatment-Emergent Adverse Events Observed were Mild to Moderate Adverse event frequency was similar across both dose groups Most adverse events were mild to moderate in severity and transient Safety profile consistent with symptoms of carcinoid syndrome and SRL treatment effects *The two cases of ALT elevation were < 3X ULN and not associated with elevated bilirubin or alkaline phosphatase. CRINETICS PHARMACEUTICALS | Treatment-Emergent Adverse Events, n (%)  Paltusotine N=36 Diarrhea  14 (38.9) Abdominal Pain 7 (19.4) Nausea 6 (16.7) Headache 6 (16.7) Flushing 5 (13.9) Fatigue 4 (11.1) Asthenia 3 (8.3) ALT Elevation 2 (5.6)* Vomiting  2 (5.6) Hypertension 2 (5.6) Myalgia 2 (5.6) Pyrexia 2 (5.6) Somnolence 2 (5.6) Urinary tract infection 2 (5.6)

Paltusotine Reduced Frequency of Key Carcinoid Syndrome Symptoms: Excess BM and Flushing *Excess bowel movements (BM) were defined as daily bowel movements above the upper limit of normal (3 per day). Excess (>3/day) Daily Frequency (7d avg) Mean (SE) Flushing Frequency For Patients with >1/day at Baseline  Excess Bowel Movement* Frequency For Patients with >3/day at Baseline Daily Frequency (7d avg) Mean (SE) P=0.02 (N=16) P<0.0001 (N=24) CRINETICS PHARMACEUTICALS | -60% -63%

Paltusotine Showed Improvements in Subjects with Elevated Bowel Movement Frequency End of each arrow represents the data from the last available week of treatment for each of the 35 subjects, including that from early dropouts. BM = Bowel Movement; RTP = Randomized Treatment Phase. Change from Baseline to Last Week of Treatment  (Patients with at least 2 Weeks of RTP Data, Ordered by Baseline Value) Baseline Bowel Movement >3 Baseline Bowel Movement ≤3 Normal BM 3 per week to 3 per day Bowel Movement Daily Frequency (From Baseline to Last Visit) Excess BM >3 per day Mean change -1.6 BM/day (N=19) Mean change -0.3 BM/day (N=16) CRINETICS PHARMACEUTICALS | Last Visit Baseline Indicates baseline BM >3 Indicates baseline BM ≤3 indicates early dropouts

Paltusotine Showed Improvements in Flushing Frequency in Majority of Subjects End of each arrow represents the data from the last available week of treatment for each of the 35 subjects, including that from early dropouts. RTP = Randomized Treatment Phase. CRINETICS PHARMACEUTICALS | Well-controlled Range Change from Baseline to Last Week of Treatment  (Patients with at Least 2 Weeks of RTP Data, Ordered by Baseline Value) Baseline Flushing >1 Baseline Flushing ≤1 Flushing Daily Frequency (From Baseline to Last Visit) Mean Change was -1.9 flushing/ day (N=25) Last Visit Baseline Indicates baseline flushing ≥1 Indicates baseline flushing <1 Indicates early dropouts Mean Change was –0.2 flushing/day (N=10)

1 Rapid Improvements in Bowel Movement Frequency Were Observed Within 2 Weeks of Treatment and Were Sustained Through Week 8 Frequency measure is based on the 14-day average during the screening period and 7-day average prior to baseline on all other timepoints. SRL = somatostatin receptor ligand. CRINETICS PHARMACEUTICALS | 6 8 Screening Baseline 4 2 Study Weeks Bowel Movement Frequency/Day Mean (SE) Bowel Movement Frequency/Day Mean (SE) 6 Baseline (washout) 4 2 Study Weeks Naïve/Untreated (n = 9) Washout Period Switching From Prior SRL (n = 27) Paltusotine Screening on SRL Paltusotine 1 3 5 7 3 5 7 8

Rapid Improvements in Flushing Frequency Were Observed Within 2 Weeks of Treatment and Were Sustained Through Week 8 Frequency measure is based on the 14-day average during the screening period and 7-day average prior to baseline on all other timepoints. SRL = somatostatin receptor ligand. Flushing Frequency/Day Mean (SE) Flushing Frequency/Day Mean (SE) Washout Period CRINETICS PHARMACEUTICALS | Naïve/Untreated (n = 9) Switching From Prior SRL (n = 27) 1 6 8 Screening Baseline 4 2 Study Weeks 6 8 Baseline (washout) 4 2 Study Weeks Screening on SRL 1 3 5 7 3 5 7 Paltusotine Paltusotine

Paltusotine Also Reduced the Severity of Key Carcinoid Syndrome Symptoms N=31 subjects with data through the Randomized Treatment Period; one subject who discontinued in the RTP dosed with paltusotine and had diary data through week 8 of the RTP; BM = bowel movement. Daily Frequency (7d avg) Mean (SE) Episodes of BM Urgency Flushing Severity N = 23 N = 23 Severity (0-10 numerical rating scale) Mean (SE) P<0.0001 (N=31) P<0.0001 (N=31) -64% -61% CRINETICS PHARMACEUTICALS |

Rapid Improvements in Episodes of BM Urgency Were Observed Within 2 Weeks of Treatment and Were Sustained Through Week 8 Frequency measure is based on the 14-day average during the screening period and 7-day average prior to baseline on all other timepoints. BM = bowel movement; SRL = somatostatin receptor ligand. CRINETICS PHARMACEUTICALS | Daily Frequency of Urgent Events (7d avg) Mean (SE) Daily Frequency of Urgent Events (7d avg) Mean (SE) Washout Period Naïve/Untreated (n = 9) Switching From Prior SRL (n = 27) Paltusotine Paltusotine 1 6 8 Screening Baseline 4 2 Study Weeks 6 Baseline (washout) 4 2 Study Weeks Screening on SRL 1 3 5 7 3 5 7 8

Rapid Improvements in Flushing Severity Were Observed Within 2 Weeks of Treatment and Were Sustained Through Week 8 Frequency measure is based on the 14-day average during the screening period and 7-day average prior to baseline on all other timepoints  SRL = somatostatin receptor ligand. CRINETICS PHARMACEUTICALS | Severity (0-10 numerical rating scale) Mean (SE) Severity (0-10 numerical rating scale) Mean (SE) Washout Period Naïve/Untreated (n = 9) Switching From Prior SRL (n = 27) 1 6 8 Screening Baseline 4 2 Study Weeks 6 Baseline (washout) 4 2 Study Weeks Screening on SRL 1 3 5 7 3 5 7 Paltusotine Paltusotine 8

Paltusotine Suppressed Serotonin Levels, a Key Biomarker in Carcinoid Syndrome Patients Baseline is last value prior to start of randomized treatment, i.e., Week 1, or Screening 1 for naïve subjects if Week 1 was missing; IQR = Interquartile range is the spread of the middle half of a data set; The upper limit of normal for Plasma 5-HIAA is 22 ng/mL. The upper limit of normal for Serum Serotonin is 541 ng/mL. CRINETICS PHARMACEUTICALS | Median Baseline 47 ng/mL Median Baseline 1064 ng/mL Washout Biomarker Percent Change from Baseline (%± IQR) Serum Serotonin (ng/mL) n=22 Plasma 5-HIAA (ng/mL) n=18 Biomarker Percent Change from Baseline (% ± IQR) Naïve Median Baseline 101 ng/mL Serum Serotonin (ng/mL) n=8 Median Baseline 2360 ng/mL Plasma 5-HIAA (ng/mL) n=7

Next Steps: Engage with FDA and Prepare for Phase 3 Start Plan to discuss the results and align on a Phase 3 study design Begin preparations to enable the initiation of Phase 3 by the end of the year Once Daily Oral Paltusotine Showed Positive Results in Carcinoid Syndrome Patients Summary: Phase 2 Results Support Proceeding to a Phase 3 Program Rapid and sustained reductions were observed in frequency and severity of bowel movements and flushing episodes with 40 mg and 80 mg Paltusotine was generally well-tolerated with no severe or serious treatment related adverse events  Overall PK profile was consistent with prior studies Serotonin and 5HIAA levels provided additional evidence for activity of paltusotine in carcinoid syndrome CRINETICS PHARMACEUTICALS | Paltusotine is an investigational drug in clinical studies for the treatment of acromegaly and carcinoid syndrome.

Market Research Supports that Paltusotine’s Emerging Profile can Address Unmet Needs for Carcinoid Syndrome Source: Primary qualitative market research conducted with US Oncologists HCPs note the extensive training required for nurses to correctly prepare and administer injectable SRLs and would welcome an oral SRL with easier prep and administration If SRLs are not administered properly, patients may not receive the full dose, missing the full benefit of the medication The SRL injections can lead to significant injection site pain and granulomas Oral Alternative HCPs predict they would offer paltusotine to all patients, and anticipate most would prefer oral SRLs over injectables Many patients are injection averse, or live far away, making it difficult to get to monthly appointments (especially elderly patients) Patient Preference “Patients who live far from the clinic, and they want to come to the clinic less frequently. Or if they said, ‘I can’t take this injection’ or ‘I don’t want to get injections,’ we can consider [Paltusotine].” - Med Onc, Community “Sometimes they don’t thaw [the medication] long enough, they’ll pinch the skin instead of flattening. And you get injection granulomas because the treatment wasn’t delivered correctly, and the patient doesn’t get the maximum benefit of the treatment.” - Med Onc, Academic HCPs say the level of symptom control demonstrated by paltusotine in phase 2 study was comparable with their clinical experience with injectable SRLs  Physicians appreciate that paltusotine targeted both flushing and diarrhea symptoms without added safety concerns Symptom Control “The two main symptoms, the diarrhea and flushing, if that’s getting better, that is a pretty good sign. The flushing is the main one for me. There is not enough available therapy for that.” - Med Onc, Community CRINETICS PHARMACEUTICALS | Paltusotine is an investigational drug in clinical studies for the treatment of acromegaly and carcinoid syndrome.

Strategy to Enable Paltusotine to Serve a Greater Number of Patients Acromegaly (11,000) Carcinoid Syndrome Switching from Depots (10,000) Carcinoid Syndrome Currently Untreated (23,000) FDA Approval & Launch Acromegaly FDA Approval & Launch Carcinoid Syndrome CRINETICS PHARMACEUTICALS | Paltusotine is an investigational drug in clinical studies for the treatment of acromegaly and carcinoid syndrome. Build HCP Experience with Acromegaly Phase 3 Study Design Supporting Both Switching and Untreated Carcinoid Syndrome Patients Build HCP Experience in Carcinoid Syndrome Paltusotine Strategic Objectives:

Crinetics is Building the Premier Fully Integrated Endocrine-focused Pharmaceutical Company *Pending alignment with FDA **Pending NDA submission, acceptance and regulatory approval ***Pending identification, creation and clinical development of new drug candidates for additional diseases 1H Commence CAH Phase 3* 2H Paltusotine acromegaly PDUFA** and launch** Human POC from new drug candidates*** New drug candidates enter development (obesity)*** Strategic Approach to Growing Long-term Value 1st Commercial Launch 1st Phase 3 Completion Sales-Funded Growth Paltusotine launch in Carcinoid Syndrome** Multiple additional commercial launches** Revenues from product sales to support growth Continuous stream of clinical catalysts New assets emerging from discovery into development ✓1Q Carcinoid Syndrome Phase 2 data readout 1Q Acromegaly PATHFNDR-2 Phase 3 data readout 2Q Initial Phase 2 data readouts in CAH and Cushing’s disease 2H File Acromegaly NDA 2H Start Carcinoid Syndrome Phase 3* New drug candidates enter development (PTH, TSH)*** CRINETICS PHARMACEUTICALS | 2024 2025 2026 - 2030 CAH: congenital adrenal hyperplasia; PTH: parathyroid hormone; TSH: thyroid stimulating hormone; POC: proof of concept

Q&A Scott Struthers, Ph.D. Founder and Chief Executive Officer Dana Pizzuti, M.D. Chief Medical & Development Officer Alan Krasner, M.D. Chief Endocrinologist Jim Hassard Chief Commercial Officer